oral antispasticity agents

When stiffness is spread across many muscles — both legs after a spinal-cord injury, a whole body after multiple sclerosis — treating each muscle one at a time is impractical, and a pill that calms tone everywhere becomes attractive. Oral antispasticity agents are exactly that: tablets, taken by mouth, that turn down the nervous system's overactivity throughout the body. Their reach is their appeal and, as it turns out, also their main drawback.

There are four common families, each working at a different point. Baclofen mimics a calming spinal-cord signal (GABA) to quiet the overactive reflex. Tizanidine dampens the excitatory drive onto motor neurons through a different receptor system. Benzodiazepines such as diazepam boost the same calming GABA signal more broadly across the brain and cord. These three act on the nervous system and so tend to cause drowsiness, weakness, and sometimes confusion. Dantrolene is the odd one out: it works inside the muscle fibre itself, blunting the contraction at its source, which spares the mind but can stress the liver. Because they act everywhere, the unavoidable trade-off is that the dose strong enough to relax the troublesome muscle often also sedates the person and weakens muscles that were doing useful work.

In rehabilitation these drugs fit best when spasticity is generalized rather than confined to one or two muscles; for focal problems an injection is usually preferred so the rest of the body is left untouched. The honest framing is that they reduce tone but not the underlying weakness, their benefit is often modest and bought at the cost of fatigue and clouded thinking, and abruptly stopping some of them — baclofen in particular — can be dangerous. They are educational categories here, not a prescription: dosing and choice belong to a clinician who knows the individual.